Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma

A Phase II Clinical Trial of Survivin-Targeted Dendritic Cell (DC) Injection for the Treatment of Newly DiagnosedGlioblastoma

The overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.

Study Overview

• Status: Not yet recruiting
• Conditions: Glioblastoma
• Intervention / Treatment: Drug: Survivin-targeted DC Cell Injection

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Zhang Xihui; Phone Number: 86+15810449839; Email: zhangxihui@tricisionbio.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age between 18 (inclusive) and 70 (inclusive) years old, with no gender restriction.
• Pathologically confirmed newly diagnosed WHO grade 4 glioblastoma multiforme (GBM).
• Positive for Survivin expression by immunohistochemistry.
• Extent of tumor resection meets grade 1 or 2 of the RANO surgical resection classification (definition ofRANO classification is provided in Appendix 1).
• Karnofsky Performance Status (KPS) score ≥ 70 prior to enrollment.
• Agree not to receive any other glioblastoma-directed therapies during the trial, except for radiotherapy,temozolomide, and targeted Survivin DC cell injection.
• Female subjects must have a negative pregnancy test; both male and female subjects agree to use non-pharmacological contraceptive measures during the trial period.
• Adequate basic hematological function: a) White blood cell count ≥ 2.0 × 10⁹/L b) Absolute neutrophilcount ≥ 1.5 × 10⁹/L c) Lymphocyte count ≥ 0.5 × 10⁹/L d) Platelet count ≥ 100 × 10⁹/L e) Hemoglobin ≥ 9.0g/dL (90 g/L).
• Expected survival ≥ 14 weeks.Expected survival ≥ 14 weeks.
• Sufficient venous access for mononuclear cell apheresis and no other contraindications toleukapheresis.
• Voluntary participation in the clinical study; subject or legal guardian fully understands the study,provides informed consent, and is willing to comply with and complete all study procedures.

Exclusion Criteria:

• History of other malignancies or concurrent other malignancies (except adequately treated carcinoma insitu of the cervix, basal cell or squamous cell skin cancer, locally confined prostate cancer after radicalresection, thyroid cancer, and ductal carcinoma in situ after radical resection).
• Contrast-enhanced MRI within 7 days after tumor surgery shows a residual lesion diameter > 1 cmcompared with preoperative status.
• Use of 5-aminolevulinic acid dye during surgery.
• Failure to complete at least two-thirds of the prescribed total dose of conformal radiotherapy over theroutine 6-week period, or failure to complete a total of 5 weeks of concurrent temozolomide chemotherapyas scheduled.
• Interval between the start of 6-week concurrent chemoradiotherapy and the completion of surgeryexceeds 50 days.
• Disease progression documented after concurrent chemoradiotherapy and prior to study treatmentinitiation.
• Hypersensitivity to any active ingredient or excipient of the investigational product (including sodiumchloride injection containing 10% human albumin), or history of allergy to penicillin or ampicillin.
• Pregnant or lactating female subjects.
• Administration of corticosteroids within 7 days prior to apheresis of peripheral blood mononuclear cells.
• Expected daily dose of corticosteroids (e.g., dexamethasone) exceeding 2 mg/day, or single doseexceeding 10 mg, within 30 days before the first dose and during the treatment period.
• Requirement for immunosuppressive agents during the study period.
• Receipt of immune cell therapy within 6 months prior to screening.
• Use of any anti-T cell therapy within 4 weeks prior to screening.
• Acute infection or unexplained fever: active viral, bacterial, or fungal infection requiring specific therapy(e.g., antibiotics); unexplained fever with body temperature > 38°C.
• Positive HIV antibody, positive syphilis antibody, positive HBsAg, positive HBcAb, positive or elevatedperipheral blood HBV DNA titer above upper limit of normal (ULN), positive anti-HCV antibody or positiveHCV RNA.
• Presence of severe or unstable cardiac, pulmonary, hepatic, renal, or coagulation disorders, including:a)Symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia;b) Acute myocardialinfarction within 6 months;c) Exacerbation of chronic obstructive pulmonary disease or other respiratorydisorders requiring hospitalization;d) SGOT (AST) > 3 × ULN, SGPT (ALT) > 3 × ULN, total bilirubin > 1.5 ×ULN;e) Serum creatinine > 1.5 × ULN;f) Coagulation parameters: international normalized ratio (INR) > 1.5 ×ULN; activated partial thromboplastin time (APTT) > 1.5 × ULN;g) Severe psychiatric disorder, poorcompliance, or lack of legal capacity to consent;h) Severe neurological disease or neurological deficit,diffuse leptomeningeal disease, or concurrent neurodegenerative disease;i) Immunodeficiency orautoimmune disease, including systemic lupus erythematosus, polymyositis, insulin-dependent diabetesmellitus, etc.
• History of organ transplantation.
• Inability or unwillingness to undergo magnetic resonance imaging (MRI) scans during the study.
• Any other circumstances in which the investigator deems the subject unsuitable for enrollment in thisclinical trial (including but not limited to poor compliance, drug abuse, etc.).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Survivin-loaded dendritic cell injection

Drug: Survivin-targeted DC Cell Injection; The standard treatment regimen for glioblastoma (GBM) is postoperative combined chemoradiotherapy plus adjuvant chemotherapy. Concurrent radiotherapy with temozolomide (TMZ) at 75 mg/m² is administered for 6 weeks in total. After an interval of 4 weeks (28 days), patients proceed to multiple cycles of adjuvant TMZ chemotherapy. Each 28-day cycle consists of oral temozolomide 150-200 mg/m² daily for 5 consecutive days, followed by a 23-day drug holiday, and the regimen is repeated every 28 days. Survivin-targeted DC cell injection regimen The Survivin-targeted DC cell injection is administered on Day 9 (±1 day) after completion of the 6-week standard concurrent chemoradiotherapy. Administration routes include intradermal and intravenous injection. Dosing is performed on Day 0, Day 14 (±1 day) and Day 28 (±2 day), for a total of 3 administrations. The total specification of Survivin-targeted DC cell injection is 6 mL per dose. The dose is divided between intradermal and intravenous route

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Primary Outcome Measure:Overall Survival (OS)	From the date of glioblastoma (GBM) surgery until death from any cause, assessed up to 36 months.

Secondary Outcome Measures

Outcome Measure	Time Frame
Progression-Free Survival (PFS)	From date of glioblastoma (GBM) surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.

Collaborators and Investigators

• Sponsor: Beijing Tricision Biotherapeutics Inc

Study record dates

Study Major Dates

• Study Start (Estimated): September 30, 2026
• Primary Completion (Estimated): September 30, 2028
• Study Completion (Estimated): September 30, 2029

Study Registration Dates

• First Submitted: July 13, 2026
• First Submitted That Met QC Criteria: July 15, 2026
• First Posted (Actual): July 20, 2026

Study Record Updates

• Last Update Posted (Actual): July 20, 2026
• Last Update Submitted That Met QC Criteria: July 15, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma
• Other Study ID Numbers: QCS-gc-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No